DrugWonks on Twitter
Tweets by @PeterPittsDrugWonks on Facebook
CMPI Videos
Video Montage of Third Annual Odyssey Awards Gala Featuring Governor Mitch Daniels, Montel Williams, Dr. Paul Offit and CMPI president Peter Pitts
Indiana Governor Mitch Daniels
Montel Williams, Emmy Award-Winning Talk Show Host
Paul Offit, M.D., Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, for Leadership in Transformational Medicine
CMPI president Peter J. Pitts
CMPI Web Video: "Science or Celebrity"
Tabloid Medicine
Check Out CMPI's Book
Physician Disempowerment:
A Transatlantic Malaise
Edited By: Peter J. Pitts
Download the E-Book Version Here
A Transatlantic Malaise
Edited By: Peter J. Pitts
Download the E-Book Version Here
CMPI Events
Donate
CMPI Reports
Blog Roll
Alliance for Patient Access
Alternative Health Practice
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog
AHRP
Better Health
BigGovHealth
Biotech Blog
BrandweekNRX
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
CNEhealth.org
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
eDrugSearch
Envisioning 2.0
EyeOnFDA
FDA Law Blog
Fierce Pharma
fightingdiseases.org
Fresh Air Fund
Furious Seasons
Gooznews
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
IgniteBlog
In the Pipeline
In Vivo
Instapundit
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
KevinMD
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
Medrants
More than Medicine
National Review
Neuroethics & Law
Newsbusters
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
PAL
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmablogger
Pharmacology Corner
Pharmagossip
Pharmamotion
Pharmalot
Pharmaceutical Business Review
Piper Report
Polipundit
Powerline
Prescription for a Cure
Public Plan Facts
Quackwatch
Real Clear Politics
Remedyhealthcare
Shark Report
Shearlings Got Plowed
StateHouseCall.org
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
TortsProf
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog
DrugWonks Blog
04/05/2007 05:50 PM |
I'm looking forward to the results of the NIH trial, but I don't think there is truly much controversy about the usefulness of this test, esp. in the right hands.
Perhaps politically, smokers aren't the most popular group, and a nicotine-blocking drug like Chantix has been a wonderful addition to my clinical arsenal. Better to be a non-smoker, whereupon the risks drop dramatically. I've written previously - 1-06 - for the Wash Post about how quitting can best be accomplished by a change in lifestyle, and how quitting decreases both short term and long term health risks.
http://www.washingtonpost.com/wp-dyn/content/article/2006/01/02/AR2006010201507.html?nav=rss_health
But for those who haven't quit, and even for those who have, screening at some regular interval has important health benefits.
Here's an interesting study just published - the mention is in Cancer Research UK:
Lung cancer screening effective for high-risk groups, says US group
FRIDAY 30 MARCH 2007
Screening high-risk individuals for lung cancer with an annual 'CT' scan may be able to detect tumours when they are most treatable, according to new US research.
The New York Early Lung Cancer Action Project study, published in the April edition of Radiology, examined the screening results of 6,295 former smokers aged over 60.
A total 124 of these people were diagnosed with lung cancer.
Almost nine in every ten of those diagnosed were found to have tumours that that had not yet spread.
Lung cancer screening is an area of intense interest, as currently most lung cancers are not detected until they are at an advanced stage when the disease is extremely difficult to treat successfully.
The new findings run counter to research published in March in the Journal of the American Medical Association, which suggested that CT screening may not significantly reduce death rates, despite detecting more cancers.
Some scientists think that CT screening may also be detecting slow-growing tumours that would not cause harm, leading people to be treated unnecessarily.
"The JAMA article was the first application of a newly developed computer model which predicted expected deaths from lung cancer, and there are numerous concerns about its validity," said Dr Henschke.
The US National Cancer Institute is funding a large trial, NLST, involving over 50,000 people, with results expected in 2009. This trial should answer questions over the effectiveness of CT screening and chest x-rays in reducing lung cancer deaths. Read More & Comment...
Perhaps politically, smokers aren't the most popular group, and a nicotine-blocking drug like Chantix has been a wonderful addition to my clinical arsenal. Better to be a non-smoker, whereupon the risks drop dramatically. I've written previously - 1-06 - for the Wash Post about how quitting can best be accomplished by a change in lifestyle, and how quitting decreases both short term and long term health risks.
http://www.washingtonpost.com/wp-dyn/content/article/2006/01/02/AR2006010201507.html?nav=rss_health
But for those who haven't quit, and even for those who have, screening at some regular interval has important health benefits.
Here's an interesting study just published - the mention is in Cancer Research UK:
Lung cancer screening effective for high-risk groups, says US group
FRIDAY 30 MARCH 2007
Screening high-risk individuals for lung cancer with an annual 'CT' scan may be able to detect tumours when they are most treatable, according to new US research.
The New York Early Lung Cancer Action Project study, published in the April edition of Radiology, examined the screening results of 6,295 former smokers aged over 60.
A total 124 of these people were diagnosed with lung cancer.
Almost nine in every ten of those diagnosed were found to have tumours that that had not yet spread.
Lung cancer screening is an area of intense interest, as currently most lung cancers are not detected until they are at an advanced stage when the disease is extremely difficult to treat successfully.
The new findings run counter to research published in March in the Journal of the American Medical Association, which suggested that CT screening may not significantly reduce death rates, despite detecting more cancers.
Some scientists think that CT screening may also be detecting slow-growing tumours that would not cause harm, leading people to be treated unnecessarily.
"The JAMA article was the first application of a newly developed computer model which predicted expected deaths from lung cancer, and there are numerous concerns about its validity," said Dr Henschke.
The US National Cancer Institute is funding a large trial, NLST, involving over 50,000 people, with results expected in 2009. This trial should answer questions over the effectiveness of CT screening and chest x-rays in reducing lung cancer deaths. Read More & Comment...
04/05/2007 09:22 AM |
I've just returned from a breakfast (kindly organized by the Government of France) with seven leading French journalists. The topic: health care. Needless to say, it was a wide-ranging conversation. A few items of note:
(1) My French is really rusty.
(2) While the systems in France and the US are very different, we share many of the same problems -- the biggest being government focus on cost rather than care.
(3) We spent a lot of time talking about how to measure the beneft of incremental innovation -- as well as what incremental innovation means and why any conversation on this topic must also include (and to a very large extent) how to expand the use of existing medicines in additional ways. We talked off-label usage.
(4) We talked comparative effectiveness and whether or not current measurements of such are legitimate ways to determine reimbursement decisions. (In other words, we spent a lot of time talking about the inappropriate ways payors -- public and private, HAS and DERP -- use general population RCTs to make "me too"/either-or decisions.
(5) And we talked about patient information. Empowering the consumer? Mon Dieu!
(6) And the fact that patient groups that are government funded are unlikely to be real patient advocates when it comes to therapeutic reimbursement decisions.
(7) And we talked about the importance of prevention programs. (Although I must add that, after the breakfast was over, they all went outside for a smoke.)
But the general theme that drove the entire conversation was, as mentioned above, what happens when cost trumps care and short-term political concerns dwarf long-term consequences.
And, no matter what language you're speaking, it sure sounds familiar. Read More & Comment...
(1) My French is really rusty.
(2) While the systems in France and the US are very different, we share many of the same problems -- the biggest being government focus on cost rather than care.
(3) We spent a lot of time talking about how to measure the beneft of incremental innovation -- as well as what incremental innovation means and why any conversation on this topic must also include (and to a very large extent) how to expand the use of existing medicines in additional ways. We talked off-label usage.
(4) We talked comparative effectiveness and whether or not current measurements of such are legitimate ways to determine reimbursement decisions. (In other words, we spent a lot of time talking about the inappropriate ways payors -- public and private, HAS and DERP -- use general population RCTs to make "me too"/either-or decisions.
(5) And we talked about patient information. Empowering the consumer? Mon Dieu!
(6) And the fact that patient groups that are government funded are unlikely to be real patient advocates when it comes to therapeutic reimbursement decisions.
(7) And we talked about the importance of prevention programs. (Although I must add that, after the breakfast was over, they all went outside for a smoke.)
But the general theme that drove the entire conversation was, as mentioned above, what happens when cost trumps care and short-term political concerns dwarf long-term consequences.
And, no matter what language you're speaking, it sure sounds familiar. Read More & Comment...
04/04/2007 01:36 PM |
"We all do no end of feeling and we mistake it for thinking. And out of it we get an aggregation which we consider a boon. Its name is public opinion. It is held in reverence. It settles everything. Some think it is the voice of God."
Mark Twain
I was going to download a webcast of Barack Obama's community meeting on healthcare in Seacoast, NH but found a newspaper account first. I am glad I did not waste the bandwidth.
If it was a battle between being banal (Barack) or bereft of insight (the attendees from Seacoast) they would still be slugging it out for first prize.
How do the Seacoasters and Obama fare? Let's restage it as drama:
Barack:"When I take office, I have to feel I have a mandate for change."
Laurie MaCray: "I don't want anymore competition - it's too confusing, it's trying to compare apples and oranges,I want a system with no deductibles, no co-pays. I want a national standard that insurers have to adhere to or not sell insurance."
Richard Friedman, MD "The problem is overuse of testing and high-priced drugs."
"We don't care how the system is managed as long as it is affordable and accessible to everyone."
Obama: ""Ultimately, (my plan) will be my best take on a comprehensive health care policy.
"I'm not going to be able to do this by myself."
My advice. Don't count on Seacoast for direction.
PS. Isn't that what people are electing YOU for? Read More & Comment...
Mark Twain
I was going to download a webcast of Barack Obama's community meeting on healthcare in Seacoast, NH but found a newspaper account first. I am glad I did not waste the bandwidth.
If it was a battle between being banal (Barack) or bereft of insight (the attendees from Seacoast) they would still be slugging it out for first prize.
How do the Seacoasters and Obama fare? Let's restage it as drama:
Barack:"When I take office, I have to feel I have a mandate for change."
Laurie MaCray: "I don't want anymore competition - it's too confusing, it's trying to compare apples and oranges,I want a system with no deductibles, no co-pays. I want a national standard that insurers have to adhere to or not sell insurance."
Richard Friedman, MD "The problem is overuse of testing and high-priced drugs."
"We don't care how the system is managed as long as it is affordable and accessible to everyone."
Obama: ""Ultimately, (my plan) will be my best take on a comprehensive health care policy.
"I'm not going to be able to do this by myself."
My advice. Don't count on Seacoast for direction.
PS. Isn't that what people are electing YOU for? Read More & Comment...
04/04/2007 11:09 AM |
Here's an interesting story by the Healthday reporter which was published in the Wash Post, Forbes, and several other places.
I was quoted extensively about neuraminidase inhibitors in the context of cautioning overuse based on FEAR, but of course avocating appropriate use.
Resistance patterns are emerging in Japan in Influenza B strains according to a new study out of the University of Tokyo.
http://www.washingtonpost.com/wp-dyn/content/article/2007/04/03/AR2007040301282.html Read More & Comment...
I was quoted extensively about neuraminidase inhibitors in the context of cautioning overuse based on FEAR, but of course avocating appropriate use.
Resistance patterns are emerging in Japan in Influenza B strains according to a new study out of the University of Tokyo.
http://www.washingtonpost.com/wp-dyn/content/article/2007/04/03/AR2007040301282.html Read More & Comment...
04/04/2007 09:21 AM |
An editorial in today’s edition of the Minneapolis Star Tribune calls for consumers to “weed out conflicts in prescription drugs.â€
According to the Star Tribune ...
“If you've taken a prescription drug lately, you might be feeling a little queasy about two recent Star Tribune stories showing that hundreds of Minnesota physicians accepted millions of dollars in fees, trips and other payments from the nation's drug manufacturers. Even assuming that doctors adhere to the highest professional standards, even assuming that the drug companies have the purest motives, this has to leave the average patient wondering if he or she got the safest, cheapest, most appropriate medicine on the market -- or the one that a drug company is pushing hardest at the moment.â€
Talk about a loaded question!
But wait, it gets worse. The editorial continues …
“Consumers who are asking that question have a new ally called the Prescription Project. It's a coalition supported by Consumer Reports magazine and funded by the Pew Charitable Trusts to reduce conflicts of interest and make sure doctors are using the best unbiased research. The Minnesota Medical Association recently endorsed the website it uses to help inform consumers.â€
But the editorial fails to mention that Consumer Reports also receives significant funding from the Engleberg Foundation – whose dollars come from no less a personage than Alfred Engleberg – who has earned northward of $100 million by successfully challenging the validity and enforceability of pharmaceutical patents and has generously shared in the resulting profits shared by generic drug makers. And, curiously enough, that funding is used to operate CR’s pharmaceutical “Savings Advisor†that offers, among other suggestions, “best buys†for Alzheimer’s medications.
An oversight on the part of the Star Tribune editorial page? Or just the most recent example of selective transparency?
Here’s a link to the full editorial:
http://www.startribune.com/561/story/1098522.html
If the Star Tribune believes that health care consumers deserve transparency, they should Gopher broke and do it right. Read More & Comment...
According to the Star Tribune ...
“If you've taken a prescription drug lately, you might be feeling a little queasy about two recent Star Tribune stories showing that hundreds of Minnesota physicians accepted millions of dollars in fees, trips and other payments from the nation's drug manufacturers. Even assuming that doctors adhere to the highest professional standards, even assuming that the drug companies have the purest motives, this has to leave the average patient wondering if he or she got the safest, cheapest, most appropriate medicine on the market -- or the one that a drug company is pushing hardest at the moment.â€
Talk about a loaded question!
But wait, it gets worse. The editorial continues …
“Consumers who are asking that question have a new ally called the Prescription Project. It's a coalition supported by Consumer Reports magazine and funded by the Pew Charitable Trusts to reduce conflicts of interest and make sure doctors are using the best unbiased research. The Minnesota Medical Association recently endorsed the website it uses to help inform consumers.â€
But the editorial fails to mention that Consumer Reports also receives significant funding from the Engleberg Foundation – whose dollars come from no less a personage than Alfred Engleberg – who has earned northward of $100 million by successfully challenging the validity and enforceability of pharmaceutical patents and has generously shared in the resulting profits shared by generic drug makers. And, curiously enough, that funding is used to operate CR’s pharmaceutical “Savings Advisor†that offers, among other suggestions, “best buys†for Alzheimer’s medications.
An oversight on the part of the Star Tribune editorial page? Or just the most recent example of selective transparency?
Here’s a link to the full editorial:
http://www.startribune.com/561/story/1098522.html
If the Star Tribune believes that health care consumers deserve transparency, they should Gopher broke and do it right. Read More & Comment...
04/03/2007 08:27 AM |
A new Austrailian report estimates that government spending on the private health insurance rebate, which costs about $3 billion Aussie dollars a year, will grow at 4.4 per cent a year -- nearly three times the expected real growth of the economy over the next 40 years.
Sound familiar?
The opposition's health spokeswoman, Nicola Roxon, said the report showed the Government was "once again shutting its eyes to the implications of chronic disease."
"The glaring gap in the previous intergenerational report was an assessment of the impact of chronic disease and preventable disease on current health expenditure, future health expenditure, workforce participation and productivity and, staggeringly, that mistake is repeated in the report released today," Ms Roxon said.
Saying it is the first step towards addressing it. Where are the American elected officials talking about the need to focus on dealing with chronic diseases (such as diabetes, hypertension, high cholesterol, etc.)?
The single biggest recent step towards getting tens of millions of Americans properly treated for chronic disease is Part D. More seniors are being properly diagnosed and treated for chronic diseases today than ever before -- a direct result of Part D.
(A fact that, mysteriously, didn't make the recent 60 Minutes story on the MMA vote.)
Beyond Part D, however, all players in the health care game (government, pharma, providers, private payors, and John Q.Patient) need to team up to address chonic disease in ALL populations ... before we find ourselves, well, down under. Read More & Comment...
Sound familiar?
The opposition's health spokeswoman, Nicola Roxon, said the report showed the Government was "once again shutting its eyes to the implications of chronic disease."
"The glaring gap in the previous intergenerational report was an assessment of the impact of chronic disease and preventable disease on current health expenditure, future health expenditure, workforce participation and productivity and, staggeringly, that mistake is repeated in the report released today," Ms Roxon said.
Saying it is the first step towards addressing it. Where are the American elected officials talking about the need to focus on dealing with chronic diseases (such as diabetes, hypertension, high cholesterol, etc.)?
The single biggest recent step towards getting tens of millions of Americans properly treated for chronic disease is Part D. More seniors are being properly diagnosed and treated for chronic diseases today than ever before -- a direct result of Part D.
(A fact that, mysteriously, didn't make the recent 60 Minutes story on the MMA vote.)
Beyond Part D, however, all players in the health care game (government, pharma, providers, private payors, and John Q.Patient) need to team up to address chonic disease in ALL populations ... before we find ourselves, well, down under. Read More & Comment...
04/02/2007 11:34 AM |
I don't want to say too much about this until the smoke clears, but some early observations:
1 - the drug was quite effective in some patients with severe irritable bowel symptoms esp. constipation, but many others with milder symptoms respond to miralax and fiber.
2 - 29 placebo controlled 1-3 month trials of over 11,600 patients receiving Zelnorm and over 7000 receiving placebo show a slight increase in the risk of cardiovascular events including angina, heart attacks, and strokes in those taking zelnorm - .01% on placebo, .1% on the drug, but these studies for the most part involve patients in higher risk groups than those i and others would prescribe it for and for some also a longer use of the drug.
3 - but the FDA acted quickly in its public advisory and Novartis has agreed to stop marketing the drug and selling it in the U.S. So why isn't the FDA being praised for its action on behalf of drug safety?
it makes sense to keep this drug in reserve for those in lower risk groups who really need it. It makes sense to not inflame this news and start criticizing everyone in sight. The FDA is being cautious - Novartis is being co-operative. Read More & Comment...
1 - the drug was quite effective in some patients with severe irritable bowel symptoms esp. constipation, but many others with milder symptoms respond to miralax and fiber.
2 - 29 placebo controlled 1-3 month trials of over 11,600 patients receiving Zelnorm and over 7000 receiving placebo show a slight increase in the risk of cardiovascular events including angina, heart attacks, and strokes in those taking zelnorm - .01% on placebo, .1% on the drug, but these studies for the most part involve patients in higher risk groups than those i and others would prescribe it for and for some also a longer use of the drug.
3 - but the FDA acted quickly in its public advisory and Novartis has agreed to stop marketing the drug and selling it in the U.S. So why isn't the FDA being praised for its action on behalf of drug safety?
it makes sense to keep this drug in reserve for those in lower risk groups who really need it. It makes sense to not inflame this news and start criticizing everyone in sight. The FDA is being cautious - Novartis is being co-operative. Read More & Comment...
04/02/2007 10:03 AM |
Can drug safety be a sometimes thing?
I pose this question based on the recent flurry of media stories on the need for new cancer treatments (see yesterday's NY Times Week in Review section) and the Abigail Alliance lawsuit that calls for greater patient access to investigational new drugs-- not to mention the debate over follow-on proteins.
(Remember, don't call them generic biologics. Words count.)
These are all important stories with significant subtexts -- most of which are entirely ignored by pols and pundits who prefer righteous indignation. Should we strive for new cancer treatment? Of course. Should patients have easier and broader access to investigational new drugs? I think yes, but there serious safety concerns that cannot just be ignored in the quest for a good headline. Follow-on proteins, same thing.
Don't get me wrong, I'm all for righteous indignation but, when it comes to drug safety, can you be for it before you are against it and still expect to be taken seriously?
Lots of well-intended verbiage in, for example Sunday's Times op-eds about the "need' without focusing on the "how," the "who," or the "how much." Many of these articles make it seem as though Big Bad Pharma is holding back on pursuing R&D for new cancer treatments because of concerns over profitability. Others blather on about Big Pharma sitting on potentially potent patents for the same reason -- with quotes from academic researchers who believe the translational gap is nothing more than the manifestation of a lazy pharmaceutical industry.
Sorry fellas -- ain't that easy.
I went through all of the articles (yesterday and today) and also did a Google search of how many times the FDA's Critical Path initiative was discussed.
Yup -- zero.
The Critical Path must not be paved with good intentions alone -- but some acknowledgement would be right and appropriate. Read More & Comment...
I pose this question based on the recent flurry of media stories on the need for new cancer treatments (see yesterday's NY Times Week in Review section) and the Abigail Alliance lawsuit that calls for greater patient access to investigational new drugs-- not to mention the debate over follow-on proteins.
(Remember, don't call them generic biologics. Words count.)
These are all important stories with significant subtexts -- most of which are entirely ignored by pols and pundits who prefer righteous indignation. Should we strive for new cancer treatment? Of course. Should patients have easier and broader access to investigational new drugs? I think yes, but there serious safety concerns that cannot just be ignored in the quest for a good headline. Follow-on proteins, same thing.
Don't get me wrong, I'm all for righteous indignation but, when it comes to drug safety, can you be for it before you are against it and still expect to be taken seriously?
Lots of well-intended verbiage in, for example Sunday's Times op-eds about the "need' without focusing on the "how," the "who," or the "how much." Many of these articles make it seem as though Big Bad Pharma is holding back on pursuing R&D for new cancer treatments because of concerns over profitability. Others blather on about Big Pharma sitting on potentially potent patents for the same reason -- with quotes from academic researchers who believe the translational gap is nothing more than the manifestation of a lazy pharmaceutical industry.
Sorry fellas -- ain't that easy.
I went through all of the articles (yesterday and today) and also did a Google search of how many times the FDA's Critical Path initiative was discussed.
Yup -- zero.
The Critical Path must not be paved with good intentions alone -- but some acknowledgement would be right and appropriate. Read More & Comment...
04/02/2007 09:34 AM |
Regular readers of DrugWonks.com know that when pundits and pols call for FDA reform, we urge them to "Show me the money" that such efforts deserve. Mostly, we're still waiting.
Now my former FDA colleague (and current CMPI Board of Advisors member) Tomas Philipson (along with two of his colleagues from the University of Chicago) asks, in a terrific guest editorial in current edition of Health Economics, "Where is the science?"
He refers, of course, to the recent IOM study which places politics before science and rhetoric before reality.
Here's a link to the editorial:
Download file
Thoughts and comments appreciated. Read More & Comment...
Now my former FDA colleague (and current CMPI Board of Advisors member) Tomas Philipson (along with two of his colleagues from the University of Chicago) asks, in a terrific guest editorial in current edition of Health Economics, "Where is the science?"
He refers, of course, to the recent IOM study which places politics before science and rhetoric before reality.
Here's a link to the editorial:
Download file
Thoughts and comments appreciated. Read More & Comment...
04/02/2007 08:31 AM |
In my column, Antidote, for M, M & M this month, I discuss Tekturna, the first in a very promising new class of hypertensive drugs. It is no accident that this drug has come in "under the radar" at a time when so much of the main stream media appetite involves bashing drugs and drug companies, rather than championing great discoveries. Of course this climate, while making companies paranoid to dot every "I" and cross every "T" can also negatively effect drug research both short and long term.
Happy Passover to all.
Here's the column:
ANTIDOTE: 4-07 by Marc Siegel MD
Novartis has a new drug that has just been approved by the FDA. It’s called Tekturna. It’s the first new class of hypertensive drugs in ten years, something well worth celebrating. But it’s “coming out party†has received little medical attention.
Why?
It’s not for lack of importance. Tekturna is a first of its kind once a day renin blocker. Hypertension afflicts close to one billion people worldwide, and is uncontrolled in 70%, leading to heart disease, kidney failure, and stroke.
Renin is a crucial hormonal trigger of the renin-angiotensin system which ultimately leads to the production of the important adrenal hormone aldosterone, while at the same time constricting the body’s arteries.
In a clinical trial involving 6,400 patients, Tekturna significantly lowered blood pressure for 24 hours and was also effective in combination with other medications. Considering that the renin-angiotensin system is an essential cause of high blood pressure and heart disease, and that the blockers already on the market that interfere with angiotensin-converting enzyme or block the receptor for angiotensin II have been highly successful and life saving, the need for an effective renin blocker is undisputed.
So now along comes the first drug of its kind, potentially the most powerful drug in the angiotensin axis, and no one pays attention. Is the blood thirsty zeal of drug company attackers so potent that it overwhelms and obscurs all positive reports about a new class of drugs? I’m afraid so. Is it more important to attack Merck over the rare side affect of Vioxx than to champion Novartis for breaking through with a new discovery? I definitely don’t think so.
If we want our drug companies to thrive and spend the billions necessary to break through with a new category of drugs, the least we can do is congratulate them when one succeeds. Those who make an unremitting habit of bashing drug companies about unforeseen side effects could cost them so much money and public embarrassment that it takes the legs out of important projects like the one that led to the birth of Tekturna. In the current climate, it is probably no coincidence that it took ten years to come up with a new category of blood pressure drugs. Read More & Comment...
Happy Passover to all.
Here's the column:
ANTIDOTE: 4-07 by Marc Siegel MD
Novartis has a new drug that has just been approved by the FDA. It’s called Tekturna. It’s the first new class of hypertensive drugs in ten years, something well worth celebrating. But it’s “coming out party†has received little medical attention.
Why?
It’s not for lack of importance. Tekturna is a first of its kind once a day renin blocker. Hypertension afflicts close to one billion people worldwide, and is uncontrolled in 70%, leading to heart disease, kidney failure, and stroke.
Renin is a crucial hormonal trigger of the renin-angiotensin system which ultimately leads to the production of the important adrenal hormone aldosterone, while at the same time constricting the body’s arteries.
In a clinical trial involving 6,400 patients, Tekturna significantly lowered blood pressure for 24 hours and was also effective in combination with other medications. Considering that the renin-angiotensin system is an essential cause of high blood pressure and heart disease, and that the blockers already on the market that interfere with angiotensin-converting enzyme or block the receptor for angiotensin II have been highly successful and life saving, the need for an effective renin blocker is undisputed.
So now along comes the first drug of its kind, potentially the most powerful drug in the angiotensin axis, and no one pays attention. Is the blood thirsty zeal of drug company attackers so potent that it overwhelms and obscurs all positive reports about a new class of drugs? I’m afraid so. Is it more important to attack Merck over the rare side affect of Vioxx than to champion Novartis for breaking through with a new discovery? I definitely don’t think so.
If we want our drug companies to thrive and spend the billions necessary to break through with a new category of drugs, the least we can do is congratulate them when one succeeds. Those who make an unremitting habit of bashing drug companies about unforeseen side effects could cost them so much money and public embarrassment that it takes the legs out of important projects like the one that led to the birth of Tekturna. In the current climate, it is probably no coincidence that it took ten years to come up with a new category of blood pressure drugs. Read More & Comment...
03/30/2007 11:44 AM |
The decision by the advisory committee to both approve Provenge using subpopulation data that ODAC did not readily provide and do so by rewriting the question provided by the FDA (asking if the drug for prostate cancer was effective as opposed to asking was the drug was substantially effective for an entire population.)
And it did so despite the fact that develop Dendreon has hardly begun to enroll patients in the post market trials the FDA and its safety mongering overlords in Congress such Ed Markey, Henry Waxman and Chuck Grassley are demanding.
For this round score it: Cancer patients 1 Postuing fearmongering pols and CYA bureaucrats 0 Read More & Comment...
And it did so despite the fact that develop Dendreon has hardly begun to enroll patients in the post market trials the FDA and its safety mongering overlords in Congress such Ed Markey, Henry Waxman and Chuck Grassley are demanding.
For this round score it: Cancer patients 1 Postuing fearmongering pols and CYA bureaucrats 0 Read More & Comment...
03/30/2007 11:27 AM |
Some key take-aways from yesterday’s joint Center for Medicine in the Public Interest/Old Dominion University conference on Comparative Effectiveness:
• My opening question to the panel was whether or not comparative effectiveness (aka evidence-based medicine, aka healthcare technology assessment, aka rational use of medicine) was focusing on cost rather than care. Practice variation vs. patient variation.
•Carolyn Clancy (Director of AHRQ) remarked that we need to capture clinical data from off-label prescribing.
• Scott Gottlieb pointed out that the value of studying Avastin vs. Erbitux or Actos vs. Januvia is of no value – but that studying Avastin+ Erbitux and Actos + Januvia would yield important clinical information.
In short – if you don’t ask the right questions, you won’t necessarily get the wrong answers – but you won’t get the answers that will help improve patient care on the clinical level.
There was much conversation about the relative benefits of RCTs vs real life epidemiological data (like off-label prescribing outcomes). Look at it this way – consider each separate pieces of software designed for different purposes. Both are relevant to any discussion of comparative effectiveness – but only one “software†is used – RCTs (by DERP, Consumers Union, etc.). We need to design a software interface that will allow these two data sets to “talk†with each other.
The time for puritanical allegiance to RCTs is coming to an end.
Panelists were also brutally honest when it came to the question of cost-over-care, the new health care realpolitk, agreeing that when it comes to Washington, DC – cost containment will win out over patient care every time.
Unfortunately I agree – that’s the way it is right now. But that has to change. As John Bridges (Johns Hopkins Bloomberg School of Public Health) commented, “There is no health care without the patient.â€
When it comes to changing the short term, politically-driven cost-over-care debate to a long term, patient-focused right-care-for-the-right-patient at-the-right-time paradigm, yesterday’s debate wasn’t the end, or even the beginning of the end but, hopefully, the end of the beginning.
And, when that day comes, it will indeed be health care's finest hour. Read More & Comment...
• My opening question to the panel was whether or not comparative effectiveness (aka evidence-based medicine, aka healthcare technology assessment, aka rational use of medicine) was focusing on cost rather than care. Practice variation vs. patient variation.
•Carolyn Clancy (Director of AHRQ) remarked that we need to capture clinical data from off-label prescribing.
• Scott Gottlieb pointed out that the value of studying Avastin vs. Erbitux or Actos vs. Januvia is of no value – but that studying Avastin+ Erbitux and Actos + Januvia would yield important clinical information.
In short – if you don’t ask the right questions, you won’t necessarily get the wrong answers – but you won’t get the answers that will help improve patient care on the clinical level.
There was much conversation about the relative benefits of RCTs vs real life epidemiological data (like off-label prescribing outcomes). Look at it this way – consider each separate pieces of software designed for different purposes. Both are relevant to any discussion of comparative effectiveness – but only one “software†is used – RCTs (by DERP, Consumers Union, etc.). We need to design a software interface that will allow these two data sets to “talk†with each other.
The time for puritanical allegiance to RCTs is coming to an end.
Panelists were also brutally honest when it came to the question of cost-over-care, the new health care realpolitk, agreeing that when it comes to Washington, DC – cost containment will win out over patient care every time.
Unfortunately I agree – that’s the way it is right now. But that has to change. As John Bridges (Johns Hopkins Bloomberg School of Public Health) commented, “There is no health care without the patient.â€
When it comes to changing the short term, politically-driven cost-over-care debate to a long term, patient-focused right-care-for-the-right-patient at-the-right-time paradigm, yesterday’s debate wasn’t the end, or even the beginning of the end but, hopefully, the end of the beginning.
And, when that day comes, it will indeed be health care's finest hour. Read More & Comment...
03/30/2007 08:45 AM |
Attention Drugwonks:
The Congressional Budget Office has lowered the 10 year cost projection of the Medicare drug benefit by $387.2 billion or 32.3 percent as compared to last year's 10 year projection.
The learning is that competition and private negotiations are saving taxpayers and beneficiaries far more money than our worthy, non-partisan government actuaries had anticipated.
And in congressional testimony before the House Budget Committee, CBO Director Orzag recentlsaid that actual prescription drug plan bids for 2007 were 15 percent lower than the bids in 2006.
Imagine that -- a government program that, per capita, actually decreases in cost from year-to-year.
Competition works. Read More & Comment...
The Congressional Budget Office has lowered the 10 year cost projection of the Medicare drug benefit by $387.2 billion or 32.3 percent as compared to last year's 10 year projection.
The learning is that competition and private negotiations are saving taxpayers and beneficiaries far more money than our worthy, non-partisan government actuaries had anticipated.
And in congressional testimony before the House Budget Committee, CBO Director Orzag recentlsaid that actual prescription drug plan bids for 2007 were 15 percent lower than the bids in 2006.
Imagine that -- a government program that, per capita, actually decreases in cost from year-to-year.
Competition works. Read More & Comment...
03/30/2007 07:34 AM |
The Washington Times
www.washingtontimes.com
Restricted treatment
By Robert Goldberg
Published March 29, 2007
Advertisement
<A TARGET="_top" HREF="http://ad.doubleclick.net/click%3Bh=v8/3525/f/52/%2a/u%3B67169689%3B3-0%3B0%3B13329423%3B4307-300/250%3B19597072/19614966/1%3B%3B%7Esscs%3D%3fhttp://servedby.advertising.com/click/site=0000725974/mnum=0000374669/optn=64?trg=http%3a%2f%2fonline.wsj.com/reg/promo/AFFEX315"><IMG SRC="http://m1.2mdn.net/490793/NEW_PP_TYPE_300x250.gif" BORDER=0></A>
This week there were two bits of news that reminded most of us that when it comes to medicine, the real crisis is not safety but the lack of treatments to prevent or at least battle disease effectively.
First, the Alzheimer's Association released revised estimates showing that the number of Americans with Alzheimer's jumped from 4 million to 5 million over the past decade, a trend which, if left unabated by new medicines, will triple to 16 million by 2030.
Second, Elizabeth Edwards and Tony Snow announced that their respective breast and colon cancers had come back and spread. The likelihood of each's survival depends on a complex combination of factors that are increasingly understood, which has translated into better drugs and longer lives. As Allan Lichter, president of the American Society of Clinical Oncologists, said recently, "in the years ahead, doctors will be able to detect cancer early with a blood test, a blood signature, if you will." The same knowledge used to detect cancers at their earliest stage will be used to develop drugs to treat them at that nascent and intimate level, making them increasingly curable. The same goes for Alzheimer's. If caught early, it can possibly be delayed for years.
Don't count on these breakthroughs anytime soon. It is taking longer than ever to bring new medicines to market. The Enhancing Drug Safety and Innovation Act currently under consideration in Congress will ensure that millions of Americans will die waiting for medicines that politicians purport to protect them from.
The act requires that before any drug is approved, a risk-management program (RiskMap) be created. As former FDA Deputy Commissioner Scott Gottlieb points out, this "legislative proposal extends the FDA's ability to restrict which physicians can prescribe a medicine, and which pharmacies can dispense it." Mr. Gottlieb notes that the FDA now limits RiskMaps to about two dozen drugs with very serious or poorly understood side effects. Getting these drugs is burdensome for patients who want them. Severe penalties await doctors and physicians who prescribe and dispense them outside of FDA guidelines.
But Congress wants to extend RiskMAPs in order to prevent possible rare side effects by limiting who can prescribe new drugs, for what uses and to whom. Under the current legislation, doctors and pharmacists who violate a RiskMap are subject to civil penalties. No doubt being accused will lead to criminal proceedings and personal injury cases. All of this means that the current legislation takes the off-label prescribing of new drugs -- though such prescribing is standard for breast cancer, Alzheimer's and mental illness -- and virtually makes it a criminal activity.
I once supported the act, known as Kennedy-Enzi. That was before its authors decided that the best way to protect the public from adverse drug events is to replicate clinical trial conditions in the real world. RiskMap could create the equivalent of a prescription-drug police state, complete with computerized monitoring by the FDA of who gets what. My friend's father was locked out -- literally -- by a computer from receiving a cancer drug on a clinical trial because his pulse was less than a tenth of second off the interval set by the FDA. No access. No treatment. If the doctor had tried giving him the drug, it would have triggered an investigation and closed down the entire trial.
This approach could be applied to millions of Americans as doctors, hospitals and pharmacists, terrified by the threat of FDA oversight, congressional hearings and lawsuits, are bludgeoned into practicing cookbook medicine. Which health plan would dare to pay for a drug that doesn't meet RiskMap mettle? The legislative push is already slowing drug approvals because FDA drug reviewers are afraid of second-guessing by the media and Congress. A new drug for diabetes-related blindness to be approved this year may now be delayed for three more years of study. A drug to treat gram-negative sepsis that was supposed to be tested against the current medicine must now be tested with a group of patients that get a placebo (a sugar pill) to satisfy the demands of Rep. Henry Waxman. Yet, in many cases, gram-negative sepsis is 100 percent fatal.
The FDA is already delaying accelerated approvals of cancer drugs until dying patients are enrolled in double-blind, randomized, placebo-controlled, post-market studies. Kennedy-Enzi wants to make this practice mandatory. That means no accelerated approval at all for cancer or Alzheimer's.
These restrictions will choke off hope, scare off innovation, give trial attorneys control over the health-care system and deny many of us longer life. The congressional assault on medical innovation is not a presidential campaign issue yet. Perhaps, thanks to the courage of Mr. Snow and Mrs. Edwards, it will be.
Robert Goldberg is vice president of the Center for Medicine in the Public Interest.. Read More & Comment...
www.washingtontimes.com
Restricted treatment
By Robert Goldberg
Published March 29, 2007
Advertisement
<A TARGET="_top" HREF="http://ad.doubleclick.net/click%3Bh=v8/3525/f/52/%2a/u%3B67169689%3B3-0%3B0%3B13329423%3B4307-300/250%3B19597072/19614966/1%3B%3B%7Esscs%3D%3fhttp://servedby.advertising.com/click/site=0000725974/mnum=0000374669/optn=64?trg=http%3a%2f%2fonline.wsj.com/reg/promo/AFFEX315"><IMG SRC="http://m1.2mdn.net/490793/NEW_PP_TYPE_300x250.gif" BORDER=0></A>
This week there were two bits of news that reminded most of us that when it comes to medicine, the real crisis is not safety but the lack of treatments to prevent or at least battle disease effectively.
First, the Alzheimer's Association released revised estimates showing that the number of Americans with Alzheimer's jumped from 4 million to 5 million over the past decade, a trend which, if left unabated by new medicines, will triple to 16 million by 2030.
Second, Elizabeth Edwards and Tony Snow announced that their respective breast and colon cancers had come back and spread. The likelihood of each's survival depends on a complex combination of factors that are increasingly understood, which has translated into better drugs and longer lives. As Allan Lichter, president of the American Society of Clinical Oncologists, said recently, "in the years ahead, doctors will be able to detect cancer early with a blood test, a blood signature, if you will." The same knowledge used to detect cancers at their earliest stage will be used to develop drugs to treat them at that nascent and intimate level, making them increasingly curable. The same goes for Alzheimer's. If caught early, it can possibly be delayed for years.
Don't count on these breakthroughs anytime soon. It is taking longer than ever to bring new medicines to market. The Enhancing Drug Safety and Innovation Act currently under consideration in Congress will ensure that millions of Americans will die waiting for medicines that politicians purport to protect them from.
The act requires that before any drug is approved, a risk-management program (RiskMap) be created. As former FDA Deputy Commissioner Scott Gottlieb points out, this "legislative proposal extends the FDA's ability to restrict which physicians can prescribe a medicine, and which pharmacies can dispense it." Mr. Gottlieb notes that the FDA now limits RiskMaps to about two dozen drugs with very serious or poorly understood side effects. Getting these drugs is burdensome for patients who want them. Severe penalties await doctors and physicians who prescribe and dispense them outside of FDA guidelines.
But Congress wants to extend RiskMAPs in order to prevent possible rare side effects by limiting who can prescribe new drugs, for what uses and to whom. Under the current legislation, doctors and pharmacists who violate a RiskMap are subject to civil penalties. No doubt being accused will lead to criminal proceedings and personal injury cases. All of this means that the current legislation takes the off-label prescribing of new drugs -- though such prescribing is standard for breast cancer, Alzheimer's and mental illness -- and virtually makes it a criminal activity.
I once supported the act, known as Kennedy-Enzi. That was before its authors decided that the best way to protect the public from adverse drug events is to replicate clinical trial conditions in the real world. RiskMap could create the equivalent of a prescription-drug police state, complete with computerized monitoring by the FDA of who gets what. My friend's father was locked out -- literally -- by a computer from receiving a cancer drug on a clinical trial because his pulse was less than a tenth of second off the interval set by the FDA. No access. No treatment. If the doctor had tried giving him the drug, it would have triggered an investigation and closed down the entire trial.
This approach could be applied to millions of Americans as doctors, hospitals and pharmacists, terrified by the threat of FDA oversight, congressional hearings and lawsuits, are bludgeoned into practicing cookbook medicine. Which health plan would dare to pay for a drug that doesn't meet RiskMap mettle? The legislative push is already slowing drug approvals because FDA drug reviewers are afraid of second-guessing by the media and Congress. A new drug for diabetes-related blindness to be approved this year may now be delayed for three more years of study. A drug to treat gram-negative sepsis that was supposed to be tested against the current medicine must now be tested with a group of patients that get a placebo (a sugar pill) to satisfy the demands of Rep. Henry Waxman. Yet, in many cases, gram-negative sepsis is 100 percent fatal.
The FDA is already delaying accelerated approvals of cancer drugs until dying patients are enrolled in double-blind, randomized, placebo-controlled, post-market studies. Kennedy-Enzi wants to make this practice mandatory. That means no accelerated approval at all for cancer or Alzheimer's.
These restrictions will choke off hope, scare off innovation, give trial attorneys control over the health-care system and deny many of us longer life. The congressional assault on medical innovation is not a presidential campaign issue yet. Perhaps, thanks to the courage of Mr. Snow and Mrs. Edwards, it will be.
Robert Goldberg is vice president of the Center for Medicine in the Public Interest.. Read More & Comment...
03/29/2007 06:54 PM |
CMPI co-sponsored a National Forum on the role comparative effectiveness research should play in health care decisionmaking with Old Dominion University medical school today....
The take away message was put best by Johns Hopkins University professor John Bridges...there is no health care without patients. Any effort to impose a cost-driven comparative effectiveness research agenda on patients will fail. It was also put best by Scott Gottlieb who said comparative effectiveness is not about false choices between two drugs, choices driven by a political agenda.
In the end, the only research that matters of the comparative kind will help determine which treatment works best for which individual and help individuals shape the nature of treatment.
Politicians who proceed otherwise will proceed at their peril. Read More & Comment...
The take away message was put best by Johns Hopkins University professor John Bridges...there is no health care without patients. Any effort to impose a cost-driven comparative effectiveness research agenda on patients will fail. It was also put best by Scott Gottlieb who said comparative effectiveness is not about false choices between two drugs, choices driven by a political agenda.
In the end, the only research that matters of the comparative kind will help determine which treatment works best for which individual and help individuals shape the nature of treatment.
Politicians who proceed otherwise will proceed at their peril. Read More & Comment...
03/29/2007 01:23 PM |
Merrill Matthews and I don't see eye-to-eye on everything when it comes to Medicare reform, but there's one thing we do agreed on ... it's working.
Have a look:
http://www.mercurynews.com/search/ci_5537368/nclick_check=1
As always, looking forward to all your thoughts and comments. Read More & Comment...
Have a look:
http://www.mercurynews.com/search/ci_5537368/nclick_check=1
As always, looking forward to all your thoughts and comments. Read More & Comment...
03/28/2007 11:37 AM |
To: Gilbert Ross, M.D.
Executive and Medical Director
American Council on Science and Health
New York
Dear Gil,
you did not read my oped carefully,
you have mischaracterized my argument for the benefit of your argument.
I never said that mortality wasn't a worthy endpoint warranting further study, i said it shouldn't be a "solo" endpoint.
I am also not alone among the thousands of internists and pulmonologists who use screening chest ct as part of a strategy for early detection, and then together with a team of top level radiologists, figure out what to do with the results. This is very clearly described in my oped, and you have distorted it.
You also should have admitted to the Journal that you know me personally, that I have done consulting work for your organization, and that this may have affected your motivation in writing this letter.
I have heard from many practicing physicians and top level researchers who have agreed with me and praised my oped. Everyone agrees that the great advances in CT technology have let to a situation where it is capable of diagnosing cancers before they leave the lung, and in the right hands, are much less likely to cause unmanageable false positives.
we can see the advantage of advanced technological screening of breast cancer, a less aggressive cancer, with the current news about MRI.
My core premise is that a practicing clinical physician like myself needs diagnostic tools like this in his arsenal that can be used in conjunction with a proper knowledge of the medical literature.
I always welcome debate with you, and appreciate your invitation for further debate, but i feel that should have occurred before you published an inaccurate letter.
Marc Siegel MD Read More & Comment...
Executive and Medical Director
American Council on Science and Health
New York
Dear Gil,
you did not read my oped carefully,
you have mischaracterized my argument for the benefit of your argument.
I never said that mortality wasn't a worthy endpoint warranting further study, i said it shouldn't be a "solo" endpoint.
I am also not alone among the thousands of internists and pulmonologists who use screening chest ct as part of a strategy for early detection, and then together with a team of top level radiologists, figure out what to do with the results. This is very clearly described in my oped, and you have distorted it.
You also should have admitted to the Journal that you know me personally, that I have done consulting work for your organization, and that this may have affected your motivation in writing this letter.
I have heard from many practicing physicians and top level researchers who have agreed with me and praised my oped. Everyone agrees that the great advances in CT technology have let to a situation where it is capable of diagnosing cancers before they leave the lung, and in the right hands, are much less likely to cause unmanageable false positives.
we can see the advantage of advanced technological screening of breast cancer, a less aggressive cancer, with the current news about MRI.
My core premise is that a practicing clinical physician like myself needs diagnostic tools like this in his arsenal that can be used in conjunction with a proper knowledge of the medical literature.
I always welcome debate with you, and appreciate your invitation for further debate, but i feel that should have occurred before you published an inaccurate letter.
Marc Siegel MD Read More & Comment...
03/28/2007 07:50 AM |
April 1st 60 Minutes will do an "expose" timed to the release of a Center for Public Integrity report showing that the pharmaceutical industry spent nearly $900 million on lobbying and campaign contributions over the past decade. Sounds like a lot right?
But the industry doesn't come close to many others in trying to push their point in a political system that frankly requires money to move messages around. Case in point, Phrma the trade group is way down the list when it comes to spending on lobbying comparrd to many DC trade groups according to CPI.
Using CPI data (1998-2004), pharma (and I don't know if they count biotech in that mix) is about even when it comes to lobbying compared to the aggregated spending of other health care interests that have been under less scrutiny and attack. Both have spent about $650 million on lobbying during that time. Add insurance companies (life and health) and the whole health care financing and delivery system has spent twice as much on lobbying as drug companies and it trade group. Electric utilities alone spent $500 million. Add in all energy related lobbying and you are close to a $ 1 billion. Banking, financing, credit concerns spend as much as pharma. So do defense and aerospace companies.
And so do all manner of government, government officials, public unions,city, county, state, sewer authorities, foreign, you name it.
Lobbying has a Jack Abrahamoff taint to it. And granted there are there are plenty of folks who set up shop and sell themselves and justify a large monthly retainer because they are able to get that all important "ask" from an important member of Congress. But ultimately how we feel about lobbying depends on our opinion on a political issue. Those who claim that the "Israel Lobby" has "too much influence" based on campaign contributions do so because they have a problem with American support for Israel. Those who claim that "Big Pharma" has "too much influence" similarly are likely to support price controls, drug importation, more FDA regulation.
So let's be honest. If you attack the Israel Lobby, you are not a Zionist.
If you attack Big Pharma's lobbying effort, you do not believe free markets are the best way to make new drugs available.
In or out. Simple as that. Read More & Comment...
But the industry doesn't come close to many others in trying to push their point in a political system that frankly requires money to move messages around. Case in point, Phrma the trade group is way down the list when it comes to spending on lobbying comparrd to many DC trade groups according to CPI.
Using CPI data (1998-2004), pharma (and I don't know if they count biotech in that mix) is about even when it comes to lobbying compared to the aggregated spending of other health care interests that have been under less scrutiny and attack. Both have spent about $650 million on lobbying during that time. Add insurance companies (life and health) and the whole health care financing and delivery system has spent twice as much on lobbying as drug companies and it trade group. Electric utilities alone spent $500 million. Add in all energy related lobbying and you are close to a $ 1 billion. Banking, financing, credit concerns spend as much as pharma. So do defense and aerospace companies.
And so do all manner of government, government officials, public unions,city, county, state, sewer authorities, foreign, you name it.
Lobbying has a Jack Abrahamoff taint to it. And granted there are there are plenty of folks who set up shop and sell themselves and justify a large monthly retainer because they are able to get that all important "ask" from an important member of Congress. But ultimately how we feel about lobbying depends on our opinion on a political issue. Those who claim that the "Israel Lobby" has "too much influence" based on campaign contributions do so because they have a problem with American support for Israel. Those who claim that "Big Pharma" has "too much influence" similarly are likely to support price controls, drug importation, more FDA regulation.
So let's be honest. If you attack the Israel Lobby, you are not a Zionist.
If you attack Big Pharma's lobbying effort, you do not believe free markets are the best way to make new drugs available.
In or out. Simple as that. Read More & Comment...
03/27/2007 10:15 PM |
The Institute of Medicine As a Profession may not accept money from big money but it does get loot from Haliburton via it's patron George Soros.....I guess hypocrisy goes down easy when it's followed by a lot of zeroes....
Here's the background.....
http://blog.foreignpolicy.com/node/3776
Soros buys Halliburton
Home » blogs » Mike Boyer
Tue, 02/27/2007 - 3:22pm.
Normally, I'm willing to overlook the hypocrisy of the liberal elite. If Al Gore and his Hollywood cronies want to fly around on gas-guzzling, atmosphere-polluting private jets while railing against global climate change, I'm willing to overlook it.
But the latest move by globe trotting, hyper-liberal billionaire George Soros borders on being too much. According to papers filed with the SEC, in the fourth quarter of 2006 Soros purchased nearly 2 million shares of ... hold your breath ... Halliburton. The Halliburton shares reportedly went for an average purchase price of $31.30 a share. That puts Soros' total investment in Halliburton at around $62.6 million, or about 2 percent of his total portfolio.
Soros, of course, is the dean of Democratic money giving. And Halliburton, of course, is the company that embodies everything the Democrats see as evil. Dick Cheney is its former chief, for goodness' sake. But Soros is also a man of contradictions. He supported campaign finance reform for years, only to declare that defeating President George W. Bush was the "central focus" of his life. To prove it, he sunk $24 million of his own "soft" money into the 2004 campaign, helping make that election one of the most divisive in modern history.
Soros' position in Halliburton is reported to be his first, which means he bought it with a full understanding of Halliburton's reputation. Soros may not see a problem with profiting from a company that has been accused of everything from sweatheart deals to cooking the books to serving U.S. troops lousy food in Iraq. The real question, however, is whether MoveOn.org, the Center for American Progress, and other organizations that have benefitted from Soros' charity will see a problem with accepting money earned off Halliburton shares? Read More & Comment...
Here's the background.....
http://blog.foreignpolicy.com/node/3776
Soros buys Halliburton
Home » blogs » Mike Boyer
Tue, 02/27/2007 - 3:22pm.
Normally, I'm willing to overlook the hypocrisy of the liberal elite. If Al Gore and his Hollywood cronies want to fly around on gas-guzzling, atmosphere-polluting private jets while railing against global climate change, I'm willing to overlook it.
But the latest move by globe trotting, hyper-liberal billionaire George Soros borders on being too much. According to papers filed with the SEC, in the fourth quarter of 2006 Soros purchased nearly 2 million shares of ... hold your breath ... Halliburton. The Halliburton shares reportedly went for an average purchase price of $31.30 a share. That puts Soros' total investment in Halliburton at around $62.6 million, or about 2 percent of his total portfolio.
Soros, of course, is the dean of Democratic money giving. And Halliburton, of course, is the company that embodies everything the Democrats see as evil. Dick Cheney is its former chief, for goodness' sake. But Soros is also a man of contradictions. He supported campaign finance reform for years, only to declare that defeating President George W. Bush was the "central focus" of his life. To prove it, he sunk $24 million of his own "soft" money into the 2004 campaign, helping make that election one of the most divisive in modern history.
Soros' position in Halliburton is reported to be his first, which means he bought it with a full understanding of Halliburton's reputation. Soros may not see a problem with profiting from a company that has been accused of everything from sweatheart deals to cooking the books to serving U.S. troops lousy food in Iraq. The real question, however, is whether MoveOn.org, the Center for American Progress, and other organizations that have benefitted from Soros' charity will see a problem with accepting money earned off Halliburton shares? Read More & Comment...
03/27/2007 06:20 PM |
As we noted The Prescription Project is " an initiative of the Boston-based nonprofit healthcare advocacy group Community Catalyst, which made headlines a little over a year ago when it sued Pfizer over its marketing claims for Lipitor. The Prescription Project is being conducted in partnership with the Institute on Medicine as a Profession (IMAP) and is funded by a USD 6 million, two-year grant from The Pew Charitable Trusts and money from George Soros.
In addition, the group has assembled a prestigious advisory committee whose members include Cathy DeAngelis, the editor-in-chief of JAMA; Steven Nissen, the president of the American College of Cardiology; and Philip A Pizzo, the dean of the Stanford School of Medicine."
Part of this campaign includes class action lawsuits initiated by the Prescription Action Litigation Project which in turn is comprised of Trial Lawyers Inc (large trial firms that seek huge monetary damages by suing corporations) and their public advocacy front, Public Citizen and various state organizations.
For instance, one mainstay of the PALP is the law firm Hagens Berman Sobol Shapiro (HBSS) which has been going after Pfizer for what is alleges are "false marketing claims by pharmaceutical giant, Pfizer. We are investigating claims made for its cardiovascular disease drug Lipitor, that encouraged doctors to prescribe the drug for patients when it was not necessary or healthy to do so." The firm is claiming that Pfizer encouraged doctors to prescribe the cholesterol drug for hypertension, chronic kidney disease, and many other unapproved illnesses besides the prevention of cardiovascular disease. ...
Hagens, Berman is famous for suing Starbucks for unbridled competition and being slapped with a $10 million penalty for violating their ".. duty of loyalty to three small water bottlers that in 2003 were close to settling a claim with Nestle Waters North America, the owner of Poland Spring Water Co." "Seattle law firm told to pay $10.8 million", Seattle Post-Intelligencer, Mar.24; Lattman, Mar. 24).
Public Citizen and the U.S. Public Interest Research Group (PIRG) works closely with Hagens Berman and other tort firms through Community Catalyst and TPP and other conduits to attack off label prescribing via fishing expeditions, testimony and now legislation at the state level to force doctors to either disclose or disgorge any money obtained from drug or biotech firms for any purpose.
This is not an effort to 'clean up' medicine. This is a witch hunt, a Stalinist effort to purge medicine of any relationship between academia, private industry and clinicians. And it is an effort to presume that off-label prescribing is both hurtful and possibly criminal behavior. Let's be clear: the goal is to create another opportunity for shaking down the drug industry and physicians. All you need are RiskMaps that prohibits and limits off-label prescribing and you have a whole new source of revenue for tort lawyers.....
Sort of like shorting currencies and buying them up. No wonder Soros is involved. Read More & Comment...
In addition, the group has assembled a prestigious advisory committee whose members include Cathy DeAngelis, the editor-in-chief of JAMA; Steven Nissen, the president of the American College of Cardiology; and Philip A Pizzo, the dean of the Stanford School of Medicine."
Part of this campaign includes class action lawsuits initiated by the Prescription Action Litigation Project which in turn is comprised of Trial Lawyers Inc (large trial firms that seek huge monetary damages by suing corporations) and their public advocacy front, Public Citizen and various state organizations.
For instance, one mainstay of the PALP is the law firm Hagens Berman Sobol Shapiro (HBSS) which has been going after Pfizer for what is alleges are "false marketing claims by pharmaceutical giant, Pfizer. We are investigating claims made for its cardiovascular disease drug Lipitor, that encouraged doctors to prescribe the drug for patients when it was not necessary or healthy to do so." The firm is claiming that Pfizer encouraged doctors to prescribe the cholesterol drug for hypertension, chronic kidney disease, and many other unapproved illnesses besides the prevention of cardiovascular disease. ...
Hagens, Berman is famous for suing Starbucks for unbridled competition and being slapped with a $10 million penalty for violating their ".. duty of loyalty to three small water bottlers that in 2003 were close to settling a claim with Nestle Waters North America, the owner of Poland Spring Water Co." "Seattle law firm told to pay $10.8 million", Seattle Post-Intelligencer, Mar.24; Lattman, Mar. 24).
Public Citizen and the U.S. Public Interest Research Group (PIRG) works closely with Hagens Berman and other tort firms through Community Catalyst and TPP and other conduits to attack off label prescribing via fishing expeditions, testimony and now legislation at the state level to force doctors to either disclose or disgorge any money obtained from drug or biotech firms for any purpose.
This is not an effort to 'clean up' medicine. This is a witch hunt, a Stalinist effort to purge medicine of any relationship between academia, private industry and clinicians. And it is an effort to presume that off-label prescribing is both hurtful and possibly criminal behavior. Let's be clear: the goal is to create another opportunity for shaking down the drug industry and physicians. All you need are RiskMaps that prohibits and limits off-label prescribing and you have a whole new source of revenue for tort lawyers.....
Sort of like shorting currencies and buying them up. No wonder Soros is involved. Read More & Comment...
Social Networks
Please Follow the Drugwonks Blog on Facebook, Twitter, LinkedIn, YouTube & RSS
Add This Blog to my Technorati Favorites